World's Best Scientists 2026 revealed!

D-Index & Metrics

Discipline name D-Index World Ranking Current World Ranking National Ranking Current National Ranking Publications Citations
Medicine 112 5065 4751 2741 2539 718 61502

Dean F. Bajorin publications per year

The chart shows the history of publications by Dean F. Bajorin between 1986 and 2025, highlighting the no. of papers published in each year and offering an overview of the publication velocity of this scholar. Dean F. Bajorin published across 40 years, from 1986 to 2025, averaging 21.4 papers a year. Output peaked at 130 publications in 2023. 43 of the 855 publications appeared in the last two years.

No. of publications
25 50 75 100 125
Bar chart. Horizontal axis: year, 1986 to 2025. Vertical axis: number of publications, 0 to 130. Peak 130 publications in 2023. 1986: 2 publications 1987: 3 publications 1988: 3 publications 1989: 2 publications 1990: 8 publications 1991: 12 publications 1992: 6 publications 1993: 9 publications 1994: 11 publications 1995: 10 publications 1996: 8 publications 1997: 10 publications 1998: 10 publications 1999: 11 publications 2000: 12 publications 2001: 9 publications 2002: 5 publications 2003: 10 publications 2004: 14 publications 2005: 18 publications 2006: 19 publications 2007: 17 publications 2008: 15 publications 2009: 10 publications 2010: 12 publications 2011: 27 publications 2012: 18 publications 2013: 24 publications 2014: 49 publications 2015: 36 publications 2016: 38 publications 2017: 51 publications 2018: 35 publications 2019: 47 publications 2020: 44 publications 2021: 35 publications 2022: 32 publications 2023: 130 publications 2024: 21 publications 2025: 22 publications
1986 2025

855 publications in total across all disciplines

View publications per year as a table
Dean F. Bajorin: publications per year, 1986 to 2025
Year Publications
1986 2
1987 3
1988 3
1989 2
1990 8
1991 12
1992 6
1993 9
1994 11
1995 10
1996 8
1997 10
1998 10
1999 11
2000 12
2001 9
2002 5
2003 10
2004 14
2005 18
2006 19
2007 17
2008 15
2009 10
2010 12
2011 27
2012 18
2013 24
2014 49
2015 36
2016 38
2017 51
2018 35
2019 47
2020 44
2021 35
2022 32
2023 130
2024 21
2025 22
Total 855
Download as CSV

Dean F. Bajorin publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Dean F. Bajorin sits on this spectrum.

No. of scientists
200 400 600 800
Bar chart with 86 bars. Horizontal axis: publications, 101–120 to 1,796+. Vertical axis: number of scientists, 0 to 922. Most scientists, 922, have 341–360 publications. The last bar groups every scientist with 1,796 publications or more. The highlighted bar, 701–720 publications, is where this scientist sits. 101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101–120 publications 1,796+

This scientist: 718 publications — 82nd percentile

82% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

View publications distribution as a table
Number of Medicine scientists by publication count, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
Publications Scientists This scientist
101–120 5
121–140 26
141–160 73
161–180 155
181–200 230
201–220 363
221–240 487
241–260 545
261–280 722
281–300 768
301–320 834
321–340 895
341–360 922
361–380 838
381–400 861
401–420 918
421–440 806
441–460 771
461–480 751
481–500 713
501–520 617
521–540 610
541–560 537
561–580 504
581–600 509
601–620 396
621–640 386
641–660 371
661–680 340
681–700 336
701–720 307 718
721–740 259
741–760 230
761–780 228
781–800 217
801–820 204
821–840 186
841–860 177
861–880 155
881–900 139
901–920 145
921–940 116
941–960 133
961–980 91
981–1,000 96
1,001–1,020 77
1,021–1,040 70
1,041–1,060 63
1,061–1,080 77
1,081–1,100 49
1,101–1,120 54
1,121–1,140 49
1,141–1,160 51
1,161–1,180 35
1,181–1,200 39
1,201–1,220 26
1,221–1,240 37
1,241–1,260 36
1,261–1,280 27
1,281–1,300 32
1,301–1,320 28
1,321–1,340 17
1,341–1,360 30
1,361–1,380 28
1,381–1,400 17
1,401–1,420 21
1,421–1,440 15
1,441–1,460 12
1,461–1,480 12
1,481–1,500 18
1,501–1,520 14
1,521–1,540 17
1,541–1,560 15
1,561–1,580 6
1,581–1,600 2
1,601–1,620 12
1,621–1,640 11
1,641–1,660 8
1,661–1,680 5
1,681–1,700 5
1,701–1,720 10
1,721–1,740 12
1,741–1,760 14
1,761–1,780 6
1,781–1,795 5
1,796+ 100
Download as CSV

Dean F. Bajorin D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Dean F. Bajorin sits on this spectrum.

No. of scientists
250 500 750 1,000
Bar chart with 75 bars. Horizontal axis: D-Index, 70–71 to 217+. Vertical axis: number of scientists, 0 to 1,027. Most scientists, 1,027, have 82–83 D-Index. The last bar groups every scientist with 217 D-Index or more. The highlighted bar, 112–113 D-Index, is where this scientist sits. 70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70–71 D-Index 217+

This scientist: 112 D-Index — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

View D-Index distribution as a table
Number of Medicine scientists by D-index, Research.com 2026 ranking edition. Based on 20,134 ranked scientists.
D-Index Scientists This scientist
70–71 226
72–73 391
74–75 574
76–77 730
78–79 891
80–81 972
82–83 1,027
84–85 1,003
86–87 960
88–89 970
90–91 922
92–93 839
94–95 808
96–97 779
98–99 668
100–101 611
102–103 630
104–105 513
106–107 541
108–109 445
110–111 429
112–113 399 112
114–115 393
116–117 318
118–119 302
120–121 287
122–123 255
124–125 256
126–127 252
128–129 230
130–131 179
132–133 168
134–135 163
136–137 159
138–139 134
140–141 134
142–143 118
144–145 109
146–147 106
148–149 74
150–151 79
152–153 80
154–155 87
156–157 57
158–159 74
160–161 69
162–163 60
164–165 53
166–167 39
168–169 42
170–171 32
172–173 39
174–175 40
176–177 28
178–179 19
180–181 23
182–183 31
184–185 18
186–187 20
188–189 22
190–191 13
192–193 21
194–195 12
196–197 12
198–199 14
200–201 15
202–203 13
204–205 10
206–207 8
208–209 4
210–211 12
212–213 11
214–215 10
216 4
217+ 98
Download as CSV

Overview

Dean F. Bajorin is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily resides within the field of Medicine, with significant contributions to several subfields including Surgery, Oncology, Molecular Biology, Pulmonary and Respiratory Medicine, and Epidemiology.

Their work encompasses topics centered on cancer research and treatment, especially related to bladder and urothelial cancers, urinary and genital oncology studies, and cancer immunotherapy and biomarkers. Additional topics include epigenetics and DNA methylation, esophageal cancer research and treatment, fibroblast growth factor research, and renal cell carcinoma treatment.

Dean F. Bajorin has published extensively in several scientific journals. The most frequent venues for their publications include:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • European Urology
  • Clinical Cancer Research
  • Annals of Oncology

Notable recent papers authored or co-authored by Bajorin include:

  • Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma (2021), New England Journal of Medicine
  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis (2020), Nature Genetics
  • Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study (2021), The Lancet Oncology
  • Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer (2020), Journal of Clinical Oncology
  • LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade (2021), Science Translational Medicine

Frequent collaborators in Bajorin's research include Jonathan E. Rosenberg, Samuel A. Funt, Hikmat Al-Ahmadie, Bernard H. Bochner, and Gopa Iyer. These co-authors have multiple joint publications, reflecting ongoing research partnerships.

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Comprehensive molecular characterization of urothelial bladder carcinoma

    John N Weinstein;Rehan Akbani;Bradley McIntosh Broom;Wenyi Wang

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

    Arjun V. Balar;Matthew D. Galsky;Jonathan E. Rosenberg;Thomas Powles

  • International germ cell consensus classification: A prognostic factor-erased staging system for metastatic germ cell cancers

    GM Mead;SP Stenning;P Cook;SD Fossa

  • First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

    Arjun V Balar;Daniel Castellano;Peter H O'Donnell;Petros Grivas

  • Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.

    Harry W. Herr;Bernard H. Bochner;Guido Dalbagni;S. Machele Donat

  • Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy

    Dean F. Bajorin;Paul M. Dodd;Madhu Mazumdar;Melissa Fazzari

  • Genome Sequencing Identifies a Basis for Everolimus Sensitivity

    Gopa Iyer;Gopa Iyer;Aphrothiti J. Hanrahan;Matthew Ivan Milowsky;Matthew Ivan Milowsky;Hikmat Al-Ahmadie

  • Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy

    Matthew D. Galsky;Noah M. Hahn;Jonathan Rosenberg;Guru Sonpavde

  • Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

    Dean F Bajorin;J Alfred Witjes;Jürgen E Gschwend;Michael Schenker

  • CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

    Padmanee Sharma;Yu Shen;Sijin Wen;Sachiko Yamada

  • Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

    Eliezer M Van Allen;Kent W. Mouw;Philip Kim;Gopa Iyer

  • Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer.

    Bernard H. Bochner;Guido Dalbagni;Michael W. Kattan;Paul Fearn

  • Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer

    Alicia Latham;Preethi Srinivasan;Yelena Kemel;Jinru Shia

  • Cancer therapy shapes the fitness landscape of clonal hematopoiesis

    Kelly L. Bolton;Ryan N. Ptashkin;Teng Gao;Lior Braunstein

  • Combination of Paclitaxel, Ifosfamide, and Cisplatin Is an Effective Second-Line Therapy for Patients With Relapsed Testicular Germ Cell Tumors

    G. Varuni Kondagunta;Jennifer Bacik;Alessia Donadio;Dean Bajorin

  • Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers

    Min Yuen Teo;Kenneth Seier;Irina Ostrovnaya;Ashley M. Regazzi

  • Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing

    Diana Mandelker;Liying Zhang;Yelena Kemel;Yelena Kemel;Zsofia K. Stadler;Zsofia K. Stadler

Frequent Co-Authors

Jonathan E. Rosenberg
Jonathan E. Rosenberg Memorial Sloan Kettering Cancer Center
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
David B. Solit
David B. Solit Memorial Sloan Kettering Cancer Center
Bernard H. Bochner
Bernard H. Bochner Memorial Sloan Kettering Cancer Center
Hikmat Al-Ahmadie
Hikmat Al-Ahmadie Memorial Sloan Kettering Cancer Center
George J. Bosl
George J. Bosl Memorial Sloan Kettering Cancer Center
Guido Dalbagni
Guido Dalbagni Memorial Sloan Kettering Cancer Center
Michael F. Berger
Michael F. Berger Memorial Sloan Kettering Cancer Center
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Harry W. Herr
Harry W. Herr Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to the traditional path of studying Medicine in the USA can open up a variety of rewarding healthcare careers. Many students are now considering flexible, online programs that provide both convenience and cost savings. For those interested in mental health practice, the fastest post master's pmhnp programs offer a quick route to becoming a psychiatric mental health nurse practitioner, addressing a growing need across the country.

If healthcare leadership and administration are your goals, a health care administration degree online can be a stepping stone to management positions in hospitals and clinics. Cost is always a concern, but there are cheapest mha programs online that make earning a master’s in healthcare administration more accessible for many students.

For those seeking the highest level of nursing practice, finding the cheapest dnp is crucial in order to pursue advanced opportunities without excessive debt. These online degree pathways allow students to work while studying and to enter in-demand healthcare careers faster and more affordably.

Best Scientists Citing Dean F. Bajorin

Trending Scientists

Recently Published Articles